NASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free CRBP Stock Alerts $44.86 +1.87 (+4.35%) (As of 11:01 AM ET) Add Compare Share Share Today's Range$43.51▼$46.0050-Day Range$33.50▼$47.0852-Week Range$3.03▼$49.87Volume112,608 shsAverage Volume695,631 shsMarket Capitalization$479.55 millionP/E RatioN/ADividend YieldN/APrice Target$61.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Corbus Pharmaceuticals alerts: Email Address Corbus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside36.0% Upside$61.00 Price TargetShort InterestBearish6.84% of Float Sold ShortDividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews Sentiment0.55Based on 11 Articles This WeekInsider TradingAcquiring Shares$10.01 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.86) to ($5.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.36 out of 5 starsMedical Sector129th out of 928 stocksPharmaceutical Preparations Industry47th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorbus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Corbus Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.84% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 14.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Corbus Pharmaceuticals is -0.65. Previous Next 2.5 News and Social Media Coverage News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Corbus Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows6 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,012,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($5.86) to ($5.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corbus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Read More CRBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRBP Stock News HeadlinesMay 15 at 1:16 AM | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Receives New Coverage from Analysts at Royal Bank of CanadaMay 13 at 8:41 PM | msn.comRBC Capital Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform RecommendationMay 13 at 7:00 AM | americanbankingnews.comStockNews.com Downgrades Corbus Pharmaceuticals (NASDAQ:CRBP) to SellMay 11, 2024 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Price Target Raised to $60.00May 9, 2024 | globenewswire.comCorbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceMay 9, 2024 | seekingalpha.comCRBP Corbus Pharmaceuticals Holdings, Inc.May 7, 2024 | investorplace.comCRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024May 1, 2024 | globenewswire.comCorbus Pharmaceuticals to Participate in the BTIG Obesity Health ForumApril 24, 2024 | globenewswire.comCorbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual MeetingApril 21, 2024 | seekingalpha.comNeutral On Corbus Pharmaceuticals' Financials And Clinical Progress In OncologyApril 20, 2024 | finance.yahoo.com7 A-Rated Aggressive Biotech Stocks to Bet On in 2024April 19, 2024 | investorplace.comThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?April 16, 2024 | msn.comHere's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price StrengthApril 2, 2024 | globenewswire.comCorbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADCMarch 22, 2024 | nasdaq.comCRBP Factor-Based Stock AnalysisMarch 17, 2024 | 247wallst.comBuffett Can't Get Enough of This Stock, Plus Other Insider BuyingMarch 13, 2024 | msn.comCorbus Pharmaceuticals files for $300M mixed shelf offeringMarch 12, 2024 | finanznachrichten.deCorbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | globenewswire.comCorbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | finance.yahoo.comCRBP Apr 2024 25.000 putMarch 11, 2024 | finance.yahoo.comCRBP Mar 2024 45.000 putMarch 10, 2024 | finance.yahoo.comCRBP Jun 2024 50.000 putMarch 10, 2024 | finance.yahoo.comCRBP Jun 2024 50.000 callMarch 8, 2024 | investorplace.comAll Three of Our Analysts AgreeMarch 7, 2024 | finance.yahoo.comCRBP Mar 2024 40.000 callSee More Headlines Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/15/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRBP CUSIPN/A CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees19Year Founded2009Price Target and Rating Average Stock Price Target$61.00 High Stock Price Target$77.00 Low Stock Price Target$46.00 Potential Upside/Downside+41.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($6.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-135.17% Return on Assets-57.70% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.69 Sales & Book Value Annual Sales$880,000.00 Price / Sales522.23 Cash FlowN/A Price / Cash FlowN/A Book Value$9.07 per share Price / Book4.74Miscellaneous Outstanding Shares10,690,000Free Float10,260,000Market Cap$459.56 million OptionableOptionable Beta2.46 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Yuval Cohen Ph.D. (Age 49)CEO & Director Comp: $907.78kMr. Sean F. Moran CPA (Age 66)M.B.A., Chief Financial Officer Comp: $609.28kMs. Lindsey SmithHead of Corporate Communications & Patient AdvocacyMs. Christina BertschHead of Human ResourcesDr. Dominic Smethurst M.A. (Age 49)M.D., Chief Medical Officer Key CompetitorsFulcrum TherapeuticsNASDAQ:FULCTheravance BiopharmaNASDAQ:TBPHPepGenNASDAQ:PEPGAcelyrinNASDAQ:SLRNLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsAltitude Crest Partners Inc.Bought 103,703 shares on 5/15/2024Ownership: 0.970%Vanguard Group Inc.Bought 257,808 shares on 5/10/2024Ownership: 4.162%Mirae Asset Global Investments Co. Ltd.Bought 24,880 shares on 5/1/2024Ownership: 0.237%Assenagon Asset Management S.A.Bought 259,456 shares on 4/24/2024Ownership: 2.469%Cormorant Asset Management, LpBought 250,000 shares on 3/7/2024Total: $10.01 M ($40.05/share)View All Insider TransactionsView All Institutional Transactions CRBP Stock Analysis - Frequently Asked Questions Should I buy or sell Corbus Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares. View CRBP analyst ratings or view top-rated stocks. What is Corbus Pharmaceuticals' stock price target for 2024? 3 Wall Street analysts have issued 12 month price targets for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $46.00 to $77.00. On average, they anticipate the company's stock price to reach $61.00 in the next year. This suggests a possible upside of 36.0% from the stock's current price. View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts. How have CRBP shares performed in 2024? Corbus Pharmaceuticals' stock was trading at $6.04 at the beginning of 2024. Since then, CRBP shares have increased by 642.7% and is now trading at $44.86. View the best growth stocks for 2024 here. When is Corbus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CRBP earnings forecast. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings results on Tuesday, March, 12th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, topping the consensus estimate of ($2.36) by $0.55. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB). Who are Corbus Pharmaceuticals' major shareholders? Corbus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.16%), Assenagon Asset Management S.A. (2.47%), Altitude Crest Partners Inc. (0.97%), Mirae Asset Global Investments Co. Ltd. (0.24%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cormorant Asset Management, Lp, Craig Stuart Millian, Sean F Moran and Yuval Cohen. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRBP) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden FINISHED On June 13th?Paradigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
